DYN Stock Analysis: Dyne Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.923m USD | 12M Return: 85.9% | US26818M1080 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 43.9M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Dyne Therapeutics, Inc. (DYN) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, that develops therapeutics for neuromuscular diseases. Incorporated in 2017 and listed on NASDAQ since September 2020, the company is building a portfolio of muscle disease programs spanning myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease, along with select rare skeletal and cardiac/metabolic muscle indications. Its work is anchored by the proprietary FORCE platform, which is designed to deliver disease-modifying payloads directly to muscle tissue.
As a clinical-stage issuer in the GICS Biotechnology sub-industry, Dyne operates a pre-commercial business model that relies on R&D investment and capital markets funding rather than product revenue, with clinical readouts and regulatory milestones typically serving as the primary value drivers for shareholders.
- DM1 and DMD clinical trial data readouts approach
- FDA designations accelerate Duchenne program development timeline
- Cash position supports pipeline through anticipated clinical milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA 1.71 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.48 > 3% & CFO -477.8m > Net Income -519.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (165.5m) vs 12m ago 45.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.22%; Δ -0.22% > 0%) |
| Interest Coverage Ratio: -33.40 > 6 (EBIT TTM -497.5m / Interest Expense TTM 14.9m) |
| A: 0.87 (Total Current Assets 937.9m - Total Current Liabilities 78.0m) / Total Assets 994.0m |
| B: -1.71 (Retained Earnings -1.70b / Total Assets 994.0m) |
| C: -0.58 (EBIT TTM -497.5m / Avg Total Assets 861.5m) |
| D: 2.41 (Book Value of Equity 702.2m / Total Liabilities 291.9m) |
| Altman-Z'' = -1.24 = CCC |
As of September 02, 2026, the stock is trading at USD 25.10 with a total of 1,629,386 shares traded. Over the past week, the price has changed by -4.71%, over one month by -0.55%, over three months by +34.73% and over the past year by +85.93%.
Current recommended Stop Loss: 23.80 (which is 5.2% or 1.3 ATR below the current price).
Dyne Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy DYN.
- StrongBuy: 7
- Buy: 6
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 39.4 | 57% |
P/B = 7.0108
P/EG = 0.19
Revenue TTM = 0.0 USD
EBIT TTM = -497.5m USD
EBITDA TTM = -495.3m USD
Long Term Debt = 199.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.37m USD (from shortTermDebt, last quarter)
Debt = 224.6m USD (corrected: LT Debt 199.3m + ST Debt 5.37m) + Leases 19.9m
Net Debt = -497.5m USD (calculated: Debt 224.6m - CCE 722.0m)
Enterprise Value = 4.43b USD (4.92b + Debt 224.6m - CCE 722.0m)
Interest Coverage Ratio = -33.40 (Ebit TTM -497.5m / Interest Expense TTM 14.9m)
EV/FCF = -9.06x (Enterprise Value 4.43b / FCF TTM -488.3m)
FCF Yield = -11.03% (FCF TTM -488.3m / Enterprise Value 4.43b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.05m) / Revenue TTM)
Tobins Q-Ratio = 4.45 (Enterprise Value 4.43b / Total Assets 994.0m)
Interest Expense / Debt = 6.63% (Interest Expense 14.9m / Debt 224.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -393.0m (EBIT -497.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.40 (Total Current Assets 937.9m / Total Current Liabilities 90.2m)
Debt / Equity = 0.32 (Debt 224.6m / totalStockholderEquity, last quarter 702.2m)
Debt / EBITDA = 1.00 (negative EBITDA) (Net Debt -497.5m / EBITDA -495.3m)
Debt / FCF = 1.02 (negative FCF - burning cash) (Net Debt -497.5m / FCF TTM -488.3m)
Total Stockholder Equity = 807.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -60.29% (Net Income -519.4m / Total Assets 994.0m)
RoE = -64.30% (Net Income TTM -519.4m / Total Stockholder Equity 807.8m)
RoCE = -49.40% (EBIT -497.5m / Capital Employed (Equity 807.8m + L.T.Debt 199.3m))
RoIC = -42.66% (negative operating profit) (NOPAT -393.0m / Invested Capital 921.4m)
WACC = 11.52% (E(4.92b)/V(5.15b) * Re(11.81%) + D(224.6m)/V(5.15b) * Rd(6.63%) * (1-Tc(0.21)))
Discount Rate = 11.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.62 | Cagr: 37.33%
[DCF] Fair Price = unknown (Cash Flow -488.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.78 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.88 | Chg30d=-14.78% | Revisions=-58% | Analysts=13
EPS current Year (2026-12-31): EPS=-3.57 | Chg30d=-16.34% | Revisions=-77% | GrowthEPS=-2.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.34 | Chg30d=-13.73% | Revisions=-42% | GrowthEPS=+6.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -71% (up=3, down=25)